2023 - Research.com Medicine in Sweden Leader Award
His primary areas of study are Breast cancer, Cancer, Internal medicine, Genetics and Oncology. His work carried out in the field of Breast cancer brings together such families of science as Obstetrics, Cancer research, Gynecology and Risk factor. His Obstetrics research incorporates elements of Relative risk and Absolute risk reduction.
His research investigates the connection between Cancer and topics such as Frameshift mutation that intersect with issues in Nonsense mutation. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Endocrinology. His study looks at the relationship between Oncology and topics such as Tamoxifen, which overlap with Chemotherapy.
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Cancer, Oncology and Gynecology. His research investigates the connection between Internal medicine and topics such as Endocrinology that intersect with problems in Diet and cancer. His research integrates issues of Cancer research, Family history and Obstetrics in his study of Breast cancer.
His research in Cancer intersects with topics in Relative risk, Incidence and Disease. In his study, Proportional hazards model is inextricably linked to Hazard ratio, which falls within the broad field of Oncology. His Risk factor research includes elements of Surgery and Epidemiology.
Håkan Olsson mainly focuses on Breast cancer, Internal medicine, Oncology, Melanoma and Cancer research. His biological study spans a wide range of topics, including Genome-wide association study, Hazard ratio, Confidence interval, Proportional hazards model and Prospective cohort study. His Internal medicine study integrates concerns from other disciplines, such as Germline mutation and Genetic correlation.
His work in Oncology covers topics such as Loratadine which are related to areas like Lymphoma, Cancer therapy and Pancreatic cancer. Håkan Olsson focuses mostly in the field of Cancer research, narrowing it down to matters related to Proteomics and, in some cases, Tumor progression. He works mostly in the field of Cancer, limiting it down to topics relating to Disease and, in certain cases, Bioinformatics, as a part of the same area of interest.
His primary areas of investigation include Melanoma, Internal medicine, Breast cancer, Oncology and Genome-wide association study. The concepts of his Melanoma study are interwoven with issues in Tumor progression, Proteomics and Immunotherapy. The study incorporates disciplines such as Trametinib and Allergy in addition to Internal medicine.
His Breast cancer research integrates issues from Gene mutation, Proportional hazards model, Hazard ratio, Prospective cohort study and Prostate cancer. His work deals with themes such as Cancer, CDKN2A, Germline mutation, Chemotherapy and Desloratadine, which intersect with Oncology. His Cancer study which covers DNA methylation that intersects with Case-control study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies
A. Antoniou;P.D.P. Pharoah;S. Narod;H.A. Risch.
American Journal of Human Genetics (2003)
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
E. E. Calle;C. W. Heath;R. J. Coates;J. M. Liff.
The Lancet (1997)
Gene-Expression Profiles in Hereditary Breast Cancer
I Hedenfalk;D Duggan;Y Chen;M Radmacher.
The New England Journal of Medicine (2001)
Cancer risks in BRCA2 mutation carriers
Journal of the National Cancer Institute (1999)
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline B. Kuchenbaecker;Karoline B. Kuchenbaecker;John L. Hopper;Daniel R. Barnes;Kelly-Anne Phillips.
Breast cancer and hormonal contraceptives : collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies
E. E. Calle;C. W. Heath;H. L. Miracle-McMahill;R. J. Coates.
The Lancet (1996)
Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease
Torgil Möller;Håkan Olsson;Jonas Ranstam.
The Lancet (2002)
Alcohol, tobacco and breast cancer - Collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease
N Hamajima;K Hirose;K Tajima;T Rohan.
British Journal of Cancer (2002)
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley.
Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies
N. Hamajima;K. Hirose;K. Tajima;T. Rohan.
Lancet Oncology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: